Abstract
A series of conjugated hyaluronic acid particles (HAP), composed of a hydrophobic anticancer drug core and hydrophilic cyclodextrin/hyaluronic acid shell, were prepared through self-assembling and characterized by (1)H NMR titration, electron microscopy, zeta potential, and dynamic light-scattering experiments. The nanometer-sized HAP thus prepared was biocompatible and biodegradable and was well-recognized by the hyaluronic acid receptors overexpressed on the surface of cancer cells, which enabled us to exploit HAP as an efficient targeted delivery system for anticancer drugs. Indeed, HAP exhibited anticancer activities comparable to the commercial anticancer drug cisplatin but with lower side effects both in vitro and in vivo.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adamantane / administration & dosage
-
Adamantane / analogs & derivatives*
-
Adamantane / therapeutic use
-
Animals
-
Breast Neoplasms / drug therapy
-
Cell Line, Tumor
-
Cisplatin / therapeutic use
-
Cyclodextrins / administration & dosage*
-
Cyclodextrins / chemical synthesis
-
Drug Carriers / chemistry
-
Drug Delivery Systems
-
Female
-
Humans
-
Hyaluronic Acid / administration & dosage*
-
Hyaluronic Acid / chemistry
-
Hydrophobic and Hydrophilic Interactions
-
Mice
-
NIH 3T3 Cells
-
Nanoparticles / chemistry*
-
Organoplatinum Compounds / administration & dosage*
-
Organoplatinum Compounds / therapeutic use
-
Prodrugs / administration & dosage*
Substances
-
Cyclodextrins
-
Drug Carriers
-
Organoplatinum Compounds
-
Prodrugs
-
Hyaluronic Acid
-
(PtCl(2)(CH(3)COO)(2)-(NH(3))(1-adamantylamine))
-
Adamantane
-
Cisplatin